Expression of Components of the Renin-Angiotensin System by Cancer Stem Cells in Renal Clear Cell Carcinoma
Abstract
:1. Introduction
2. Materials and Methods
2.1. RCCC Tissue Samples
2.2. Histology and Immunohistochemical Staining
2.3. Immunofluorescence Staining
2.4. Image Analysis
2.5. RT-qPCR
2.6. Western Blotting
3. Results
3.1. Renin, ACE2, PRR and AT2R Were Expressed in RCCC Tissue Samples
3.2. ACE2, PRR and AT2R but Not Renin Were Expressed by CSCs in RCCC Tissue Samples
3.3. Renin, PRR, ACE, ACE2, and AT1R Transcripts Were Expressed in RCCC Tissue Samples
3.4. Western Blotting Confirmed the Presence of PRR, ACE, ACE2 and AT2R Proteins in RCCC Tissue Samples
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Jonasch, E.; Gao, J.; Rathmell, W.K. Renal cell carcinoma. BMJ 2014, 349, g4797. [Google Scholar] [CrossRef]
- Muglia, V.F.; Prando, A. Renal cell carcinoma: Histological classification and correlation with imaging findings. Radiol. Bras. 2015, 48, 166–174. [Google Scholar] [CrossRef] [Green Version]
- Koul, H.; Huh, J.-S.; Rove, K.O.; Crompton, L.; Koul, S.; Meacham, R.B.; Kim, F.J. Molecular aspects of renal cell carcinoma: A review. Am. J. Cancer Res. 2011, 1, 240–254. [Google Scholar] [PubMed]
- Ridge, C.; Pua, B.; Madoff, D. Epidemiology and Staging of Renal Cell Carcinoma. Semin. Intervent. Radiol. 2014, 31, 003–008. [Google Scholar] [CrossRef] [Green Version]
- Cane, R.; Kennedy-Smith, A.; Brasch, H.D.; Savage, S.; Marsh, R.W.; Itinteang, T.; Tan, S.T.; Itinteang, T. Characterization of Cancer Stem Cells in Renal Clear Cell Carcinoma. J. Stem Cell Regen. Biol. 2019, 5, 6–17. [Google Scholar] [CrossRef]
- Nabi, S.; Kessler, E.R.; Bernard, B.; Flaig, T.W.; Lam, E.T. Renal cell carcinoma: A review of biology and pathophysiology. F1000 Research 2018, 7, 307. [Google Scholar] [CrossRef] [PubMed]
- Maher, E. Von Hippel-Lindau Disease. Curr. Mol. Med. 2004, 4, 833–842. [Google Scholar] [CrossRef]
- Chow, W.-H.; Dong, L.M.; Devesa, S.S. Epidemiology and risk factors for kidney cancer. Nat. Rev. Urol. 2010, 7, 245–257. [Google Scholar] [CrossRef]
- Escudier, B.; Porta, C.; Schmidinger, M.; Rioux-Leclercq, N.; Bex, A.; Khoo, V.; Gruenvald, V.; Horwich, A. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2016, 27, 58–68. [Google Scholar] [CrossRef]
- Kreso, A.; Dick, J.E. Evolution of the cancer stem cell model. Cell Stem Cell 2014, 14, 275–291. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huang, B.; Huang, Y.J.; Yao, Z.J.; Chen, X.; Guo, S.J.; Mao, X.P.; Wang, D.H.; Chen, J.X.; Qiu, S.P. Cancer Stem Cell-Like Side Population Cells in Clear Cell Renal Cell Carcinoma Cell Line 769P. PLoS ONE 2013, 8, e68293. [Google Scholar] [CrossRef] [Green Version]
- Bussolati, B.; Camussi, G. Cancer Stem Cells and Renal Carcinoma. In Advances in Cancer Stem Cell Biology; Springer: New York, NY, USA, 2012; pp. 211–220. [Google Scholar]
- Peired, A.J.; Sisti, A.; Romagnani, P. Renal cancer stem cells: Characterization and targeted therapies. Stem Cells Int. 2016, 2016, 1–12. [Google Scholar] [CrossRef] [Green Version]
- Myszczyszyn, A.; Czarnecka, A.M.; Matak, D.; Szymanski, L.; Lian, F.; Kornakiewicz, A.; Bartnik, E.; Kukwa, W.; Kieda, C.; Szczylik, C. The role of hypoxia and cancer stem cells in renal cell carcinoma pathogenesis. Stem Cell Rev. Rep. 2015, 11, 919–943. [Google Scholar] [CrossRef] [Green Version]
- Takahashi, K.; Yamanaka, S. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell 2006, 126, 663–676. [Google Scholar] [CrossRef] [Green Version]
- Yu, J.; Vodyanik, M.A.; Smuga-Otto, K.; Antosiewicz-Bourget, J.; Frane, J.L.; Tian, S.; Nie, J.; Jonsdottir, G.A.; Ruotti, V.; Stewart, R.; et al. Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells. Science 2007, 318, 1917–1920. [Google Scholar] [CrossRef]
- Cheng, B.; Yang, G.; Jiang, R.; Cheng, Y.; Yang, H.; Pei, L.; Qiu, X. Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: A meta-analysis. Oncotarget 2016, 7, 65862–65875. [Google Scholar] [CrossRef]
- Peach, M.J. Renin-angiotensin system: Biochemistry and mechanisms of action. Physiol. Rev. 1977, 57, 313–370. [Google Scholar] [CrossRef]
- Bradshaw, A.R.; Wickremesekera, A.C.; Brasch, H.D.; Chibnall, A.M.; Davis, P.F.; Tan, S.T.; Itinteang, T. Glioblastoma Multiforme Cancer Stem Cells Express Components of the Renin–Angiotensin System. Front. Surg. 2016, 3, 51. [Google Scholar] [CrossRef] [Green Version]
- Itinteang, T.; Dunne, J.C.; Chibnall, A.M.; Brasch, H.D.; Davis, P.F.; Tan, S.T. Cancer stem cells in moderately differentiated oral tongue squamous cell carcinoma express components of the renin–angiotensin system. J. Clin. Pathol. 2016, 69, 942–945. [Google Scholar] [CrossRef] [Green Version]
- Ram, R.S.; Brasch, H.D.; Dunne, J.C.; Davis, P.F.; Tan, S.T.; Itinteang, T. Cancer Stem Cells in Moderately Differentiated Lip Squamous Cell Carcinoma Express Components of the Renin–Angiotensin System. Front. Surg. 2017, 4, 30. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Featherston, T.; Yu, H.H.; Dunne, J.C.; Chibnall, A.M.; Brasch, H.D.; Davis, P.F.; Tan, S.T.; Itinteang, T. Cancer Stem Cells in Moderately Differentiated Buccal Mucosal Squamous Cell Carcinoma Express Components of the Renin–Angiotensin System. Front. Surg. 2016, 3, 52. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nallaiah, S.; Lee, V.M.Y.; Brasch, H.D.; de Jongh, J.; van Schaijik, B.; Marsh, R.; Tan, S.T.; Itinteang, T. Cancer stem cells within moderately differentiated head and neck cutaneous squamous cell carcinoma express components of the renin-angiotensin system. J. Plast. Reconstr. Aesthetic Surg. 2019, 72, 1484–1493. [Google Scholar] [CrossRef]
- Siljee, S.; Buchanan, O.; Brasch, H.D.; Bockett, N.; Patel, J.; Paterson, E.; Purdie, G.L.; Davis, P.F.; Itinteang, T.; Tan, S.T. Cancer Stem Cells in Metastatic Head and Neck Cutaneous Squamous Cell Carcinoma Express Components of the Renin-Angiotensin System. Cells 2021, 10, 243. [Google Scholar] [CrossRef]
- Wickremesekera, A.C.; Brasch, H.D.; Lee, V.M.; Davis, P.F.; Parker, A.; Koeck, H.; Itinteang, T.; Tan, S.T.; Wickremesekera, A.R.; Brasch, H.D.; et al. Cancer stem cell subpopulations in metastatic melanoma to the brain express components of the renin-angiotensin system. J. Cancer Metastasis Treat. 2019, 5. [Google Scholar] [CrossRef] [Green Version]
- Siljee, S.; Pilkington, T.; Brasch, H.D.; Bockett, N.; Patel, J.; Paterson, E.; Davis, P.F.; Tan, S.T. Cancer Stem Cells in Head and Neck Metastatic Malignant Melanoma Express Components of the Renin-Angiotensin System. Life 2020, 10, 268. [Google Scholar] [CrossRef]
- Narayanan, A.; Wickremesekera, S.K.; Van Schaijik, B.; Marsh, R.W.; Brasch, H.D.; Tan, S.T.; Itinteang, T. Cancer stem cells in liver metastasis from colon adenocarcinoma express components of the renin-angiotensin system. J. Cancer Metastasis Treat. 2019, 2019, 36. [Google Scholar] [CrossRef]
- Munro, M.J.; Wickremesekera, A.C.; Davis, P.F.; Marsh, R.; Tan, S.T.; Itinteang, T. Renin-angiotensin system and cancer: A review. Integr. Cancer Sci. Ther. 2017, 4, 1–6. [Google Scholar] [CrossRef]
- Koh, S.P.; Wickremesekera, A.C.; Brasch, H.D.; Marsh, R.; Tan, S.T.; Itinteang, T. Expression of Cathepsins B, D, and G in Isocitrate Dehydrogenase-Wildtype Glioblastoma. Front. Surg. 2017, 4, 28. [Google Scholar] [CrossRef] [Green Version]
- Featherston, T.; Marsh, R.W.; van Schaijik, B.; Brasch, H.D.; Tan, S.T.; Itinteang, T. Expression and Localization of Cathepsins B, D, and G in Two Cancer Stem Cell Subpopulations in Moderately Differentiated Oral Tongue Squamous Cell Carcinoma. Front. Med. 2017, 4, 100. [Google Scholar] [CrossRef] [Green Version]
- Mehrotra, S.; Wickremesekera, S.K.; Brasch, H.D.; Van Schaijik, B.; Marsh, R.W.; Tan, S.T.; Itinteang, T. Expression and Localization of Cathepsins B, D and G in Cancer Stem Cells in Liver Metastasis From Colon Adenocarcinoma. Front. Surg. 2018, 5, 40. [Google Scholar] [CrossRef]
- Featherston, T.; Brasch, H.D.; Siljee, S.; van Schaijik, B.; Patel, J.; de Jongh, J.; Marsh, R.; Itinteang, T.; Tan, S. Cancer Stem Cells in Head and Neck Cutaneous Squamous Cell Carcinoma Express Cathepsins. PRS Glob. Open 2020, 1–9. [Google Scholar] [CrossRef]
- George, A.J.; Thomas, W.G.; Hannan, R.D. The renin–angiotensin system and cancer: Old dog, new tricks. Nat. Rev. Cancer 2010, 10, 745–759. [Google Scholar] [CrossRef] [PubMed]
- Polakis, P. The many ways of Wnt in cancer. Curr. Opin. Genet. Dev. 2007, 17, 45–51. [Google Scholar] [CrossRef]
- Shibayama, Y.; Fujimori, T.; Nguyen, G.; Hirose, T.; Totsune, K.; Ichihara, A.; Kitada, K.; Nakano, D.; Kobori, H.; Kohno, M.; et al. (Pro)renin receptor is crucial for Wnt/β-catenin-dependent genesis of pancreatic ductal adenocarcinoma. Sci. Rep. 2015, 5, 8854. [Google Scholar] [CrossRef] [PubMed]
- Deshayes, F.; Nahmias, C. Angiotensin receptors: A new role in cancer? Trends Endocrinol. Metab. 2005, 16, 293–299. [Google Scholar] [CrossRef] [PubMed]
- Asgharzadeh, F.; Hashemzehi, M.; Moradi-Marjaneh, R.; Hassanian, S.M.; Ferns, G.A.; Khazaei, M.; Avan, A. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers as therapeutic options in the treatment of renal cancer: A meta-analysis. Life Sci. 2020, 242, 117181. [Google Scholar] [CrossRef]
- Tikellis, C.; Thomas, M.C. Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. Int. J. Pept. 2012, 2012, 1–8. [Google Scholar] [CrossRef]
- Santos, R.A.S.; Simoes e Silva, A.C.; Maric, C.; Silva, D.M.R.; Machado, R.P.; de Buhr, I.; Heringer-Walther, S.; Pinheiro, S.V.B.; Lopes, M.T.; Bader, M.; et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. USA 2003, 100, 8258–8263. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ager, E.I.; Neo, J.; Christophi, C. The renin-angiotensin system and malignancy. Carcinogenesis 2008, 29, 1675–1684. [Google Scholar] [CrossRef] [Green Version]
- Xu, J.; Fan, J.; Wu, F.; Huang, Q.; Guo, M.; Lv, Z.; Han, J.; Duan, L.; Hu, G.; Chen, L.; et al. The ACE2/angiotensin-(1-7)/Mas receptor axis: Pleiotropic roles in cancer. Front. Physiol. 2017, 8, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Doi, C.; Egashira, N.; Kawabata, A.; Maurya, D.K.; Ohta, N.; Uppalapati, D.; Ayuzawa, R.; Pickel, L.; Isayama, Y.; Troyer, D.; et al. Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice. BMC Cancer 2010, 10, 67. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sun, H.; Li, T.; Zhuang, R.; Cai, W.; Zheng, Y. Do renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?: Evidence from a meta-analysis including 55 studies. Medicine 2017, 96, e6394. [Google Scholar] [CrossRef]
- Derosa, L.; Izzedine, H.; Albiges, L.; Escudier, B. Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma. Oncol. Rev. 2016, 10, 54–59. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sobczuk, P.; Szczylik, C.; Porta, C.; Czarnecka, A. Renin angiotensin system deregulation as renal cancer risk factor (Review). Oncol. Lett. 2017, 14, 5059–5068. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- McKay, R.R.; Rodriguez, G.E.; Lin, X.; Kaymakcalan, M.D.; Hamnvik, O.-P.R.; Sabbisetti, V.S.; Bhatt, R.S.; Simantov, R.; Choueiri, T.K. Angiotensin System Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma. Clin. Cancer Res. 2015, 21, 2471–2479. [Google Scholar] [CrossRef] [Green Version]
- Miyajima, A.; Kosaka, T.; Asano, T.; Asano, T.; Seta, K.; Kawai, T.; Hayakawa, M. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res. 2002, 62, 4176–4179. [Google Scholar] [PubMed]
- Pinter, M.; Jain, R.K. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci. Transl. Med. 2017, 9, eaan5616. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Araújo, W.F.; Naves, M.A.; Ravanini, J.N.; Schor, N.; Teixeira, V.P.C. Renin-angiotensin system (RAS) blockade attenuates growth and metastatic potential of renal cell carcinoma in mice. Urol. Oncol. Semin. Orig. Investig. 2015, 33, 389.e1–389.e7. [Google Scholar] [CrossRef]
- Michel, M.C.; Wieland, T.; Tsujimoto, G. How reliable are G-protein-coupled receptor antibodies? Naunyn. Schmiedebergs. Arch. Pharmacol. 2009, 379, 385–388. [Google Scholar] [CrossRef] [Green Version]
- Benicky, J.; Hafko, R.; Sanchez-Lemus, E.; Aguilera, G.; Saavedra, J.M. Six commercially available angiotensin II AT1 receptor antibodies are non-specific. Cell. Mol. Neurobiol. 2012, 32, 1353–1365. [Google Scholar] [CrossRef] [Green Version]
- Herrera, M.; Sparks, M.A.; Alfonso-Pecchio, A.R.; Harrison-Bernard, L.M.; Coffman, T.M. Lack of specificity of commercial antibodies leads to misidentification of angiotensin type 1 receptor protein. Hypertension 2013, 61, 253–258. [Google Scholar] [CrossRef] [Green Version]
- Elliott, K.J.; Kimura, K.; Eguchi, S. Lack of specificity of commercial antibodies leads to misidentification of angiotensin type-1 receptor protein. Hypertension 2013, 61, e31. [Google Scholar] [CrossRef] [Green Version]
- Wakahara, S.; Konoshita, T.; Mizuno, S.; Motomura, M.; Aoyama, C.; Makino, Y.; Kato, N.; Koni, I.; Miyamori, I. Synergistic expression of angiotensin-converting enzyme (ACE) and ACE2 in human renal tissue and confounding effects of hypertension on the ACE to ACE2 ratio. Endocrinology 2007, 148, 2453–2457. [Google Scholar] [CrossRef] [Green Version]
- Peters, J.; Wanka, H.; Peters, B.; Hoffmann, S. A renin transcript lacking exon 1 encodes for a non-secretory intracellular renin that increases aldosterone production in transgenic rats. J. Cell. Mol. Med. 2008, 12, 1229–1237. [Google Scholar] [CrossRef] [Green Version]
- Peters, J. Cytosolic pro renin and the matter of intracellular renin actions. Front. Biosci. 2013, S5, S366. [Google Scholar] [CrossRef] [Green Version]
- Li, Z.; Zhou, L.; Wang, Y.; Miao, J.; Hong, X.; Hou, F.F.; Liu, Y. (Pro)renin receptor is an amplifier of Wnt/β-catenin signaling in kidney injury and fibrosis. J. Am. Soc. Nephrol. 2017, 28, 2393–2408. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kojima, T.; Shimazui, T.; Hinotsu, S.; Joraku, A.; Oikawa, T.; Kawai, K.; Horie, R.; Suzuki, H.; Nagashima, R.; Yoshikawa, K.; et al. Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling. Oncogene 2009, 28, 297–305. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, D.; Wang, P.; Yu, Y.; Huang, B.; Zhang, X.; Xu, C.; Zhao, X.; Yin, Z.; He, Z.; Jin, M.; et al. Tumor-preventing activity of aspirin in multiple cancers based on bioinformatic analyses. PeerJ 2018, 2018. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Majid, S.; Saini, S.; Dahiya, R. Wnt signaling pathways in urological cancers: Past decades and still growing. Mol. Cancer 2012, 11, 1–13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Larrinaga, G.; Pérez, I.; Sanz, B.; Blanco, L.; López, J.I.; Cándenas, M.L.; Pinto, F.M.; Gil, J.; Irazusta, J.; Varona, A. Angiotensin-converting enzymes (ACE and ACE2) are downregulated in renal tumors. Regul. Pept. 2010, 165, 218–223. [Google Scholar] [CrossRef]
- Errarte, P.; Beitia, M.; Perez, I.; Manterola, L.; Lawrie, C.H.; Solano-Iturri, J.D.; Calvete-Candenas, J.; Unda, M.; López, J.I.; Larrinaga, G. Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients. PLoS ONE 2017, 12, e0181711. [Google Scholar] [CrossRef]
- Urata, H.; Kinoshita, A.; Misono, K.S.; Bumpus, F.M.; Husain, A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J. Biol. Chem. 1990, 265, 22348–22357. [Google Scholar] [CrossRef]
- Sugimoto, M.; Yamaoka, Y.; Shirai, N.; Furuta, T. Role of renin-angiotensin system in gastric oncogenesis. J. Gastroenterol. Hepatol. 2012, 27, 442–451. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ibaraki, T.; Muramatsu, M.; Takai, S.; Jin, D.; Maruyama, H.; Orino, T.; Katsumata, T.; Miyazaki, M. The relationship of tryptase- and chymase-positive mast cells to angiogenesis in stage I non-small cell lung cancer. Eur. J. Cardio-Thoracic Surg. 2005, 28, 617–621. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Diaconu, N.-C.; Rummukainen, J.; Naukkarinen, A.; Mättö, M.; Harvima, R.J.; Pelkonen, J.; Harvima, I.T. Mast cell chymase is present in uterine cervical carcinoma and it detaches viable and growing cervical squamous carcinoma cells from substratum in vitro. Arch. Dermatol. Res. 2011, 303, 499–512. [Google Scholar] [CrossRef]
- Feng, H.; Wei, X.; Pang, L.; Wu, Y.; Hu, B.; Ruan, Y.; Liu, Z.; Liu, J.; Wang, T. Prognostic and Immunological Value of Angiotensin-Converting Enzyme 2 in Pan-Cancer. Front. Mol. Biosci. 2020, 7, 1–13. [Google Scholar] [CrossRef]
- Zhang, Z.; Li, L.; Li, M.; Wang, X. The SARS-CoV-2 host cell receptor ACE2 correlates positively with immunotherapy response and is a potential protective factor for cancer progression. Comput. Struct. Biotechnol. J. 2020, 18, 2438–2444. [Google Scholar] [CrossRef]
- Chai, P.; Yu, J.; Ge, S.; Jia, R.; Fan, X. Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: A pan-cancer analysis. J. Hematol. Oncol. 2020, 13, 1–5. [Google Scholar] [CrossRef] [PubMed]
- Petty, W.J.; Miller, A.A.; Mccoy, T.P.; Gallagher, P.E.; Tallant, E.A.; Torti, F.M. Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin. Cancer Res. 2009, 15, 7398–7404. [Google Scholar] [CrossRef] [Green Version]
- Zheng, S.; Yang, Y.; Song, R.; Yang, X.; Liu, H.; Ma, Q.; Yang, L.; Meng, R.; Tao, T.; Wang, S.; et al. Ang-(1-7) promotes the migration and invasion of human renal cell carcinoma cells via Mas-mediated AKT signaling pathway. Biochem. Biophys. Res. Commun. 2015, 460, 333–340. [Google Scholar] [CrossRef]
- Dolley-Hitze, T.; Jouan, F.; Martin, B.; Mottier, S.; Edeline, J.; Moranne, O.; Le Pogamp, P.; Belaud-Rotureau, M.-A.; Patard, J.-J.; Rioux-Leclercq, N.; et al. Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? Br. J. Cancer 2010, 103, 1698–1705. [Google Scholar] [CrossRef] [Green Version]
- Hii, S.-I.I.; Nicol, D.L.D.; Gotley, D.C.; Thompson, L.C.; Green, M.K.; Jonsson, J.R.J. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br. J. Cancer 1998, 77, 880–883. [Google Scholar] [CrossRef] [Green Version]
- Izzedine, H.; Derosa, L.; Le Teuff, G.; Albiges, L.; Escudier, B. Hypertension and angiotensin system inhibitors: Impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Ann. Oncol. 2015, 26, 1128–1133. [Google Scholar] [CrossRef]
- Keizman, D.; Huang, P.; Eisenberger, M.A.; Pili, R.; Kim, J.J.; Antonarakis, E.S.; Hammers, H.; Carducci, M.A. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. Eur. J. Cancer 2011, 47, 1955–1961. [Google Scholar] [CrossRef] [Green Version]
- Miyajima, A.; Yazawa, S.; Kosaka, T.; Tanaka, N.; Shirotake, S.; Mizuno, R.; Kikuchi, E.; Oya, M. Prognostic Impact of Renin–Angiotensin System Blockade on Renal Cell Carcinoma After Surgery. Ann. Surg. Oncol. 2015, 22, 3751–3759. [Google Scholar] [CrossRef] [PubMed]
- Tatokoro, M.; Fujii, Y.; Kawakami, S.; Saito, K.; Koga, F.; Matsuoka, Y.; Iimura, Y.; Masuda, H.; Kihara, K. Phase-II trial of combination treatment of interferon-α, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. Cancer Sci. 2011, 102, 137–143. [Google Scholar] [CrossRef]
- Villar-Cheda, B.; Costa-Besada, M.A.; Valenzuela, R.; Perez-Costas, E.; Melendez-Ferro, M.; Labandeira-Garcia, J.L. The intracellular angiotensin system buffers deleterious effects of the extracellular paracrine system. Cell Death Dis. 2017, 8, e3044. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tadevosyan, A.; Xiao, J.; Surinkaew, S.; Naud, P.; Merlen, C.; Harada, M.; Qi, X.; Chatenet, D.; Fournier, A.; Allen, B.G.; et al. Intracellular Angiotensin-II Interacts With Nuclear Angiotensin Receptors in Cardiac Fibroblasts and Regulates RNA Synthesis, Cell Proliferation, and Collagen Secretion. J. Am. Heart Assoc. 2017, 6. [Google Scholar] [CrossRef] [PubMed]
- Cook, J.L.; Re, R.N. Review: Lessons from in vitro studies and a related intracellular angiotensin II transgenic mouse model. Am. J. Physiol. Integr. Comp. Physiol. 2012, 302, R482–R493. [Google Scholar] [CrossRef] [Green Version]
- Warnecke, C.; Sürder, D.; Curth, R.; Fleck, E.; Regitz-Zagrosek, V. Analysis and functional characterization of alternatively spliced angiotensin II type 1 and 2 receptor transcripts in the human heart. J. Mol. Med. 1999, 77, 718–727. [Google Scholar] [CrossRef] [PubMed]
- Roth, I.M.; Wickremesekera, A.C.; Wickremesekera, S.K.; Davis, P.F.; Tan, S.T. Therapeutic Targeting of Cancer Stem Cells via Modulation of the Renin-Angiotensin System. Front. Oncol. 2019, 9, 745. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tan, D.; Roth, I.; Wickremesekera, A.; Davis, P.; Kaye, A.; Mantamadiotis, T.; Stylli, S.; Tan, S. Therapeutic Targeting of Cancer Stem Cells in Human Glioblastoma by Manipulating the Renin-Angiotensin System. Cells 2019, 8, 1364. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Gender | |
---|---|
Male | 7 (46.7%) |
Female | 8 (53.3%) |
Mean age (range) | 66.6 (36.6–87.5) years |
ISUP Grade | |
Grade 2 | 8 (53.3%) |
Grade 3 | 7 (46.7%) |
Tumor stage | |
Stage pT1x | 2 (13.3%) |
Stage pT1a | 5 (33.3%) |
Stage pT1b | 1 (6.7%) |
Stage pT2a | 2 (13.3%) |
Stage pT3a | 5 (33.3%) |
Status | |
Alive | 11 (73.3%) |
Deceased | 4 (26.7%) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Siljee, S.; Milne, B.; Brasch, H.D.; Bockett, N.; Patel, J.; Davis, P.F.; Kennedy-Smith, A.; Itinteang, T.; Tan, S.T. Expression of Components of the Renin-Angiotensin System by Cancer Stem Cells in Renal Clear Cell Carcinoma. Biomolecules 2021, 11, 537. https://doi.org/10.3390/biom11040537
Siljee S, Milne B, Brasch HD, Bockett N, Patel J, Davis PF, Kennedy-Smith A, Itinteang T, Tan ST. Expression of Components of the Renin-Angiotensin System by Cancer Stem Cells in Renal Clear Cell Carcinoma. Biomolecules. 2021; 11(4):537. https://doi.org/10.3390/biom11040537
Chicago/Turabian StyleSiljee, Sam, Bridget Milne, Helen D. Brasch, Nicholas Bockett, Josie Patel, Paul F. Davis, Andrew Kennedy-Smith, Tinte Itinteang, and Swee T. Tan. 2021. "Expression of Components of the Renin-Angiotensin System by Cancer Stem Cells in Renal Clear Cell Carcinoma" Biomolecules 11, no. 4: 537. https://doi.org/10.3390/biom11040537